Viral core protein inhibitors - Pipeline Insight, 2024

This “Viral core protein inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Viral core protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Viral core protein inhibitors Understanding

Viral core protein inhibitors: Overview

The core or capsid protein is essential to virion assembly and structure, interacts with several host cell proteins, and is the most conserved of all of the viral proteins across the six major genotypes. The core protein oligomerizes during the process of viral assembly, and a screen evaluating dimerization, a process mediated by the N-terminal domain, identified small-molecule inhibitors from a library of indoline derivatives. Core inhibitors, also known as capsid assembly modulators or core protein allosteric modulators, are a novel class of HBV replication inhibitors that have been shown to act at multiple steps in the HBV lifecycle.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Viral core protein inhibitors R&D. The therapies under development are focused on novel approaches for Viral core protein inhibitors.

Viral core protein inhibitors Emerging Drugs Chapters

This segment of the Viral core protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Viral core protein inhibitors Emerging Drugs

Vebicorvir: Assembly Biosciences Vebicorvir, first-generation core inhibitor is being developed by Assembly Biosciences. In Phase 2 clinical trials, first-generation core inhibitor vebicorvir (VBR) administered with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy demonstrated a favorable safety profile and led to greater viral suppression of both HBV DNA and HBV pg RNA than NrtI therapy alone. VBR is advancing in multiple Phase 2 combination studies. Vebicorvir have been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of chronicHBVinfection.

Morphothiadine: HEC Pharm Morphothiadine (GLS4), a HAP (heteroaryl-di-hydro-pyrimidines) compound is being developed by HEC Pharm Group, for the oral treatment of hepatitisB.

Viral core protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Viral core protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Viral core protein inhibitors

There are approx. 5+ key companies which are developing the Viral core protein inhibitors. The companies which have their Viral core protein inhibitors drug candidates in the most advanced stage, i.e. Phase II include, Assembly Biosciences.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Viral core protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Viral core protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Viral core protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Viral core protein inhibitors drugs.

Viral core protein inhibitors Report Insights

• Viral core protein inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Viral core protein inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Viral core protein inhibitors drugs?
• How many Viral core protein inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Viral core protein inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Viral core protein inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Viral core protein inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Assembly Biosciences
• HEC Pharm
• Janssen Sciences Ireland
• Enanta Pharmaceuticals
• Fujian Cosunter Pharmaceutical
• Door Pharmaceuticals

Key Products

• Vebicorvir
• GLS4
• Bersacapavir
• EDP 514
• GST HG141
• ABI H3733
• ABI 4334

Research programme: HBV core protein modulators


This product will be delivered within 1-3 business days.